Patients with acute myeloid leukemia (AML) are at risk to develop severe infections whose
invasive aspergillosis (IA). These infections are leading to an important morbidity and
mortality. Antifungal prophylaxis is recommended by posaconazole for AML patients during
neutropenia induced by induction chemotherapy. Their application is not uniform.